Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Nov 15:4:71.
doi: 10.1186/s40425-016-0182-5. eCollection 2016.

Application of the Immunoscore as prognostic tool for hepatocellular carcinoma

Annacarmen Petrizzo  1 , Luigi Buonaguro  1
Affiliations
Editorial

Application of the Immunoscore as prognostic tool for hepatocellular carcinoma

Annacarmen Petrizzo et al. J Immunother Cancer. .

Abstract

To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of prognosis in solid tumors. However, the clinical outcome can be significantly different in patients with the same TNM stage. Therefore, many efforts have been made aiming to define new prognostic parameters. Indeed, analyses conducted in large cohorts of colorectal cancer patients emphasized the prognostic value of tumor-infiltrating lymphocytes, leading to the development of a prognostic score referred to as "Immunoscore". In this commentary, we recapitulate the study by Gabrielson and colleagues, recently published in Cancer Immunology Research, addressing the role of intratumoral CD3+ and CD8+ T cells as well as as prognostic markers for hepatocellular carcinoma. The authors demonstrate that Immunoscore represents a valuable prognostic marker in patients with hepatocellular carcinoma who have undergone primary tumor resection, supporting its application in a tumor setting other than colorectal cancer.

Keywords: Hepatocellular carcinoma; Immunoscore; Programmed Death Ligand 1 (PD-L1); TNM Stage; Tumor-infiltrating lymphocytes.

PubMed Disclaimer

Comment on

  • Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, Island E, Satoskar R, Banovac F, Jha R, Kachhela J, Feng P, Zhang T, Tesfaye A, Prins P, Loffredo C, Marshall J, Weiner L, Atkins M, He AR. Gabrielson A, et al. Cancer Immunol Res. 2016 May;4(5):419-30. doi: 10.1158/2326-6066.CIR-15-0110. Epub 2016 Mar 11. Cancer Immunol Res. 2016. PMID: 26968206 Free PMC article.

References

    1. European Association for the Study of the Liver EOfRaToC EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi: 10.1016/j.jhep.2011.12.001. - DOI - PubMed
    1. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer. 2014;120:2824–2838. doi: 10.1002/cncr.28730. - DOI - PubMed
    1. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013;59:897–903. doi: 10.1016/j.jhep.2013.05.031. - DOI - PubMed
    1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928. doi: 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E. - DOI - PubMed
    1. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31:840-845. - PubMed

MeSH terms